Home Exclusive: Phrontline Biopharma Closes Nearly USD 40 Million Series A, Nearing USD 100 Million in a Year

Exclusive: Phrontline Biopharma Closes Nearly USD 40 Million Series A, Nearing USD 100 Million in a Year

Nov 13, 2026 08:00 CST Updated 09:52
Phrontline Biopharma

Antibody-Drug Conjugate (ADC) Developer

Oriza Holdings

Early-stage Equity Investment Management Institution

Decheng Capital

Life Sciences Investment Firms

Jifeng Ventures

Venture Capital Firms

Med-Fine Capital

Venture Capital Firm

C&D Emerging Industry Equity Investment

Equity Asset Management Firm

Lapam Capital

Venture Capital Institutions in the Biomedical Field

VCBeat has learned that Phrontline Biopharma, a developer of next-generation antibody-drug conjugates (ADCs), today announced the completion of a nearly USD 40 million Series A financing round. The round was co-led by Oriza Seed and Decheng Capital, with Lapam Capital, Jifeng Ventures, Med-Fine Capital, Songqing Capital, and C&D Emerging Industry Equity Investment participating, and DAS Capital serving as exclusive financial advisor.


This is the second round Phrontline has closed within a single year, following its USD 60 million Pre-A+ round in November 2025, bringing the cumulative amount raised across the two rounds to nearly USD 100 million.



The proceeds will be mainly used to accelerate clinical development of core pipeline assets, advance IND filings for differentiated reserve pipeline candidates, build a new payload platform, and further expand international collaborations and the company's capitalization process.

 

Building a Next-Generation Bispecific Dual-Toxin ADC Platform to Break the Homogenization Deadlock of Conventional ADCs


Phrontline is one of the earliest biopharmaceutical companies in China to focus on bispecific antibody-drug conjugates (BsAb-ADCs) and dual-payload ADCs. Given the high degree of homogeneity among conventional ADCs in target selection and payload mechanisms, the company has made broadening the therapeutic window its core objective. It has built a full-chain ADC R&D platform spanning antibody engineering, linker-payload chemistry, and functional evaluation, forming a core technology system with fully independent intellectual property rights. Its payload system now covers multiple mechanisms of action, including topoisomerase I inhibitors (topo1i), microtubule inhibitors, DNA alkylating agents, ATR inhibitors, NMT inhibitors (NMTi), and pan-RAS inhibitors, providing the basis for the synergistic combination design of dual payloads.


TJ101 is a bispecific antibody ADC targeting EGFR x B7-H3. It is one of the earliest pipelines of its kind initiated in China and one of the few such ADCs worldwide that have entered clinical development. At the 2026 Congress of the European Society for Medical Oncology (ESMO), the company presented Phase Ia clinical results for TJ101: the candidate showed good safety and tolerability, and encouraging antitumor activity was observed in multiple tumor types, including non-small cell lung cancer, small cell lung cancer, prostate cancer, and urothelial carcinoma, all without driver gene mutations.


TJ102 is a first-in-class bispecific dual-payload ADC targeting FRα x CDH6. The company first disclosed its preclinical data at the 2025 AACR Annual Meeting, where the two payloads demonstrated a marked synergistic effect. TJ102 has now become the first ADC of its kind worldwide to enter clinical development.


Global Recognition: Leading the Bispecific and Dual-Payload ADC Track


Phrontline is currently the only biotech company in the world that has completed out-licensing deals in both the bispecific ADC and dual-payload ADC segments. The successive conclusion of these external collaborations has validated the global value of the company's platform technologies and pipeline assets, and laid the foundation for the international expansion and commercialization pathways of its subsequent pipelines.